DEARBORN, Mich. (PRWEB)
January 28, 2020

The Association of Affiliated Pharmacies and Apothecaries (AAPA), the nation’s fastest growing independent pharmacy buying group, announced its partnership with Zova™, one of the world’s most trusted providers of THC-free (0.00% non-detectable), hemp-sourced CBD products, to build the AAPA CBD AdvantEdge™ program. The program provides immediate and exclusive CBD product access to AAPA member pharmacies at wholesale acquisition costs (WAC) that are on average 50 percent lower than any other competitive offering on the market today. In addition, the CBD products distributed through the program are backed by the AAPA AdvantEdge™ CBD Purity & Safety Guarantee.

AAPA and Zova™ teamed up to offer independent pharmacy members products based on hundreds of years of cumulative experience in hemp “seed to table” practices used by certified farms, non-GMO sources, and cGMP grade facilities. The AAPA AdvantEdge™ CBD Purity & Safety Guarantee lets pharmacists know where their products are coming from and exactly what ingredients are in them. Every product has a QR code that links to the product’s third-party lab’s certificate of analysis.

“AAPA studied the CBD industry looking for a company that aligned with our mission to continue providing members with pathways to success,” Gerry Crocker, CEO at AAPA. “After months of comparing and analyzing processes, systems, and the overall integrity of the products offered, Zova was far and away the best option for bringing a broad spectrum, hemp-sourced, THC-free CBD options and deals to our members.”

“At Zova, we make pharmacists and their patients our top priority,” says Ed Saleh, CEO at Zova. “Because our executive team consists of pharmacists with years of experience, specialized in meeting patients’ needs, we understand the challenges healthcare professionals face. So, we created a CBD product line that can assist pharmacists in serving their patients.”

The broad-spectrum CBD product line is made in the USA and includes sublingual tinctures in multiple concentrations and flavors as well as topical salves, gel capsules, gummies, moisturizers, and pet-focused options. AAPA also has developed a starter kit for pharmacies new to CBD product lines.

“Staying on the forefront of this industry allows our member base to reinvent business models and better serve their patient’s ever-changing needs,” added Crocker. “Bringing the CBD line to our members has the potential to increase profit margins by 100 percent. Being able to offer deeper savings on CBD products strengthens the member pharmacy’s standings within the community and helps to drive their business success.”

Learn more about the AAPA CBD AdvantEdge™ program at http://www.aaparx.com.

About the AAPA

Built by pharmacists for independent pharmacies in 1996, the Association of Affiliated Pharmacies and Apothecaries (AAPA) helps independent pharmacy owners proactively gain better control over profitability and growth through access to the industry’s deepest, most aggressive brand and generic drug discount offerings; business insights into more profitable opportunities outside the normal pharmacy niche; and advocacy services that safeguard the pharmacy’s role and success throughout the care continuum. The organization’s nonprofit arm will continue to provide leadership on legislative issues and other community causes and maintain active student chapters. Learn more at http://www.aaparx.com.

About Zova™

Zova™ was founded by a team of pharmacists who wanted to create a product line that made pharmacies and patients their top priority. Part of a multitude of partnerships across North and South America, and with hundreds of years of cumulative experience in hemp “seed to table” production, including farms and cGMP grade facilities, Zova uses non-GMO seeds while working hand-in-hand with organic farms to ensure the highest seed quality from inception to product creation.

Zova’s approach allows them to provide access to high-quality, innovative hemp products using core values of Integrity, Innovation, Persistence & Compassion. These values help the company stay on task in utilizing innovations that focus on the tenets of natural science. To find out more about Zova, visit http://www.zovacbd.com.

Share article on social media or email:

SAN JOSE, Calif. (PRWEB)
January 28, 2020

Santa Clara Family Health Plan (SCFHP) announced its plan to open a Community Resource Center (CRC) to provide the residents of East San Jose with local access to SCFHP services. The CRC will be open to the entire community and will offer convenient in-person customer service, enrollment assistance, health education classes, and case management, provided in the main languages spoken by Medi-Cal beneficiaries.

Along with providing health care navigation resources, the CRC will be developed as an inclusive space for Community Based Organizations and local safety net agencies working to address the social determinants of health. The CRC will be an affordable and conveniently located alternative for organizations to host workshops, conduct classes, or provide trainings that will help SCFHP members and local residents.

“As Santa Clara County’s local Medi-Cal managed care plan, we are excited to work with the community to develop the CRC into a valued resource for health, wellbeing, and collaboration in East San Jose,” said Christine M. Tomcala, Chief Executive Officer of SCFHP.

The CRC will be located in the Capitol Square Mall at North Capitol Avenue and McKee Road. The official name of the CRC will be the Santa Clara Family Health Plan Blanca Alvarado Community Resource Center, in honor of Blanca Alvarado’s distinguished history of service to the community.

“We are honored to name the CRC after Blanca Alvarado, who through community leadership and public service has dedicated her life to advocating for social justice and human rights. Blanca Alvarado embodies the spirit of care that is central to SCFHP’s mission and to our vision for the CRC,” said Ms. Tomcala.

Currently, over 87,500 SCFHP members live in East San Jose. The location of the CRC will greatly reduce critical barriers for members and local residents seeking assistance – transportation and time. By providing convenient access to services that promote healthy and active lifestyles, the East San Jose CRC will support visitors in becoming advocates for their own health and wellbeing and that of their families.

Construction is scheduled to begin in early 2020, with the opening of the Blanca Alvarado Community Resource Center targeted for mid-2020.

About Santa Clara Family Health Plan

SCFHP is a local, community-based health plan dedicated to improving the health and well-being of the residents of Santa Clara County. Working in partnership with providers and community organizations, we serve our neighbors through our Medi-Cal and Cal MediConnect (Medicare-Medicaid Plan) health insurance plans. SCFHP began offering coverage in 1997 and is now proud to provide services to over 239,000 residents of Santa Clara County. Through devotion to outstanding service and care for the community, SCFHP is committed to providing quality, affordable health insurance to the underserved in Santa Clara County’s diverse population. For more information, visit http://www.scfhp.com.

Share article on social media or email:

PUNE, India and SEATTLE (PRWEB)
January 28, 2020

The World Health Organization (WHO) has prequalified PNEUMOSIL®, a vaccine against a leading cause of deadly childhood pneumonia—the pneumococcus bacterium. This is a major step toward improving pneumococcal conjugate vaccine affordability and enabling sustainable access for children and families in low- and middle-income countries.

The vaccine was developed through a collaboration between Serum Institute of India, Pvt., Ltd. (SIIPL) and PATH with a grant from the Bill & Melinda Gates Foundation. It is expected to protect children on par with other pneumococcal conjugate vaccines at a price that is more affordable for low- and middle-income countries.

Representatives from the Serum Institute of India, Pvt., Ltd. and the Bill & Melinda Gates Foundation will speak about the development and WHO prequalification of PNEUMOSIL® at the first-ever Global Forum on Childhood Pneumonia on January 29-31, 2020.

The announcement of this prequalification is an important milestone toward alleviating one of the biggest barriers that countries face in sustainably accessing pneumococcal conjugate vaccines—price. WHO prequalification allows PNEUMOSIL® to be procured by the United Nations agencies and Gavi, the Vaccine Alliance. “PNEUMOSIL® can be manufactured at high volume with current capacity at 100 million doses per annum, which will be augmented to over 150 million doses per annum in two to three years. It will be made available at a target Gavi price of around US$2 per dose, which is roughly 30% less than the current Gavi price for these kinds of vaccines,” says Dr. Rajeev Dhere, executive director of SIIPL.

“The vaccine provides an alternate vaccine for low- and middle-income countries to ensure lifesaving access to pneumococcal disease prevention over the long term,” explains Dr. Mark Alderson, director of PATH’s pneumococcal vaccine project.

Pneumococcal conjugate vaccines are difficult for many countries to afford without considerable donor financial support but have helped significantly reduce pneumococcal deaths and illness where introduced. And though donor support has been key in helping to increase country access, implementing and sustaining pneumococcal vaccine programs continues to be difficult for many countries. PNEUMOSIL® brings forward a more affordable option that can make a pneumococcal vaccine accessible and free up country and donor funds for other health priorities.

“There has been unprecedented demand for the pneumococcal vaccine from Gavi-supported countries,” says Dr. Seth Berkley, CEO of Gavi, the Vaccine Alliance. “Within the last decade, we have supported the vaccination of 185 million children against this leading killer of children—but there is still work to be done. This new vaccine gives us more options in the fight to ensure no child dies from this preventable and treatable disease.”

“Vaccines are one of the best investments we can make to give every child a healthy start at life and build stronger communities and economies,” said Dr. Keith Klugman, director of the pneumonia team at the Bill & Melinda Gates Foundation. “As pneumonia continues to be the leading cause of death for young children worldwide, we welcome this new vaccine that will allow for more children to be protected from this debilitating disease.”

In addition to pneumonia, the pneumococcus bacterium causes other serious, life-threatening diseases like meningitis and sepsis. It is estimated to cause nearly 400,000 deaths in children under five years of age each year worldwide.

PNEUMOSIL® covers the types of the bacterium most likely to cause serious illness in low- and middle-income countries and is manufactured in the most efficient way possible. This reduces costs while preserving quality.

“Pneumococcal conjugate vaccines are among the most complex vaccines to manufacture. As a vaccine developed and produced in India that will benefit the world, PNEUMOSIL®’s WHO prequalification is a landmark achievement,” adds Mr. Neeraj Jain, PATH country director in India.

A recent PATH-sponsored Phase 3 clinical study of PNEUMOSIL® in infants in The Gambia was conducted prior to WHO prequalification at the MRC Unit in The Gambia—part of the London School of Hygiene and Tropical Medicine—and provided the pivotal results for the data package required for WHO prequalification. The vaccine met all primary and secondary endpoints in the study, with key findings showing the vaccine to have an acceptable safety profile and to generate a protective immune response similar to a WHO-prequalified comparator pneumococcal vaccine without interfering with other routine childhood immunizations. These results were presented at the 2019 European Symposium on Pediatric Infectious Diseases and a study manuscript is in preparation for peer-reviewed publication. Other study collaborators included FHI Clinical and the WHO Reference Laboratory for Pneumococcal Serology at the Great Ormond Street Institute of Child Health, University College London.

###

Additional resources for media: Fact sheet: pneumococcal disease, pneumococcal conjugate vaccines, and PNEUMOSIL®

About Serum Institute of India, Pvt., Ltd.

Serum Institute of India, Pvt., Ltd. (SIIPL), based in Pune, India, today is the largest manufacturer of diphtheria, tetanus, pertussis (DTP) and measles, mumps, rubella (MMR) vaccines and supplies its products to United Nations agencies and more than 160 countries. SIIPL’s MenAfriVac® meningococcal serogroup A conjugate vaccine, which was specifically developed for sub-Saharan Africa, is acknowledged as a remarkable success by the vaccine community. It is a policy and commitment of SIIPL to make new vaccines available at affordable prices to the children of the developing world. http://www.seruminstitute.com.

About PATH

PATH is a global organization that works to accelerate health equity by bringing together public institutions, businesses, social enterprises, and investors to solve the world’s most pressing health challenges. With expertise in science, health, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales solutions—including vaccines, drugs, devices, diagnostics, and innovative approaches to strengthening health systems worldwide. http://www.path.org

Share article on social media or email:

In the last 25 years of treating the toughest cases, I can honestly say that I’ve never been more excited about what we can offer through our latest innovations for those living with chronic illness.

NASHVILLE, Tenn. (PRWEB)
January 28, 2020

For the past 25 years, Biologix Center For Optimum Health has helped over ten thousand people from around the world who had previously exhausted conventional and alternative medicine treatments with what was essentially considered incurable, or at least non-responsive chronic illness. Biologix Center specializes in treating Lyme disease, POTS, ALS, multiple sclerosis, chronic fatigue syndrome, fibromyalgia, multiple chemical sensitivity, histamine intolerance, mast cell activation syndrome, mold toxicity, chronic digestive issues, as well as illnesses of unknown origin.

Biologix Center’s founder, Dr. David Jernigan, is a published author and innovator of multiple healthcare technologies. He is also an internationally recognized leader in Biological and Bioregulatory Medicine and the treatment of chronic illness. With the precision testing he has developed, much of the guesswork common in doctoring is eliminated by enabling the doctors to essentially access the software of the body and instantly determine what is wrong and what to do about it, instead of waiting days or weeks for lab tests that are often of minimal value.

The range of new innovations that power this highly-individualized and comprehensive approach often succeed where conventional medicine and pharmaceuticals fail. Dr. Jernigan states:

“There is so much that has gone wrong in most of our patients that our doctors spend one hour every day of the one to three-week all-inclusive programs of care, in order to work through all the systems and issues of the body within their patients, and up to another 4 hours a day are spent on supportive therapies. This is a maximum applied effort to quickly and gently restore a person to optimum health.”

Historically based out of Wichita, Kansas, Biologix Center is transferring its operations to a new location in Franklin, Tennessee, just minutes south of Nashville. The new Nashville location will offer Stem Cell Therapy and Induced Native Phage Therapy (INPT). When asked about the new Nashville location, Dr. Jernigan stated:

“In the last 25 years of treating the toughest cases, I can honestly say that I’ve never been more excited about what we can offer through our latest innovations for those living with chronic illness. The new drug-free treatments are proving to be so incredibly effective that they are helping those who have previously never been helped before, by even the most well known doctors and clinics.”

Biologix Center is currently scheduling patients at the Nashville location, which is set to open on March 16th. The center is also hiring more DC’s, MD’s, nurses, and support staff. If you are interested in scheduling a treatment program or a free case review with Dr. David Jernigan, please call the Biologix Patient Care Coordinator at (855) 525-5984. If you are interested in working with the Biologix Center, please contact Michelle Pfeifer at mpfeifer@biologixcenter.com.

###

Biologix Center is an internationally recognized clinical facility that uses extremely precise and scientifically advanced alternative treatments and therapies to heal people with, non-responsive chronic illness of all kinds. Biologix seeks to treat the root causes of chronic illness by promoting the functional integrity of the entire human person, thereby restoring the body’s ability to heal itself. For more information, please contact Keeley Dodd, at kdodd@biologixcenter.com , or visit https://biologixcenter.com.

Dr. David Jernigan received his Bachelor’s degree in Nutrition at Park University, graduating with honors, and his doctorate in Chiropractic Medicine at Cleveland University-Kansas City. He is a board-certified Doctor of Natural Medicine with an emphasis on chronic infections and chronic illness. Post-graduate studies include natural and Anthroposophical medicine in Germany and Biological/Bioregulation Medicine with the famed-father of European Biological Medicine, Dr. Thomas Rau, MD, of the Paracelsus Clinic of Switzerland. He is board-certified in Botanical Medicine through the University of Colorado, School of Pharmacy, and trains doctors in advanced homeopathy and bioenergetic medicine. Dr. Jernigan has contributed to the advancement of medical science with several exciting inventions, including BioResonance Scanning, Matrix Interface Resonance Scanning, Fractal Frequency Modulation, NeuroPhotonic Therapy, Induced Native Phage Therapy, and NeuroCardial Synchronization.

Share article on social media or email:

PHILADELPHIA (PRWEB)
January 28, 2020

Bainbridge Health, a spinoff company of the Children’s Hospital of Philadelphia, is excited to expand its network of hospitals to include Children’s Mercy Kansas City, a top-ranked pediatric hospital in Kansas City, MO. Through the partnership, Bainbridge Health will provide Children’s Mercy with its Med O.S.© Infusion Pump Safety Solution to enhance visibility on medication use data and prevent avoidable harm associated with medication errors.

Each year, medication errors lead to more than 7,000 deaths in the United States alone and are currently one of the leading causes of harm in the hospital setting (1). Bainbridge Health remains committed to preventing medication errors and ensuring the safety of all those who seek care. The company’s Med O.S.© Platform organizes and analyzes infusion pump data to help clinicians better understand how medications are being administered to patients and inform quality improvement initiatives.

With the addition of Children’s Mercy, Bainbridge Health’s pediatric medication dataset is among the largest in the country. “From our roots in a pediatric hospital system, improving quality and safety for children is at the heart of our mission. As pediatric providers come together to share resources and best practices, care will only get better. We are thrilled to welcome such a prestigious and committed provider of children’s health to our network,” said Joseph Kaupp, CEO of Bainbridge Health.

Children’s Mercy is one of the best children’s hospitals in America by U.S. News and World Report, ranking in all 10 pediatric specialties for the fifth consecutive year. Every day its employees strive to fulfill their mission of improving the health and well-being of children by providing comprehensive family-centered health care, committing to the highest level of clinical and psychosocial care, and exhibiting research, educational and service excellence.

About Bainbridge Health

Bainbridge Health was developed in the Children’s Hospital of Philadelphia and in collaboration with leading adult and pediatric hospitals. Bainbridge helps healthcare organizations unlock the value of their medication data to prevent errors, reduce costs and maintain compliance. Our team seeks to empower clinical partners to put an end to pivot tables, ad-hoc dashboard requests and manually intensive data-clerking. To learn more, please visit bainbridgehealth.com.

Join the Conversation

Each quarter, Bainbridge Health hosts a webinar and discussion on industry topics pertinent to the safety and stewardship of medications. To view our past webinars, click here. To get updates on our upcoming webinars, click here.

Share article on social media or email:

PARK RIDGE, Ill. (PRWEB)
January 28, 2020

Christopher J. Bergin, M.D. is proud to announce that fellowship-trained orthopedic spine surgeon Dr. Steven Fineberg is the newest surgeon to join The Spine Center at 1875 Dempster Street, Suite 425 in Park Ridge. Dr. Fineberg is currently accepting new patients.

Dr. Fineberg earned his medical degree from the Sackler School of Medicine at Tel Aviv University in Israel, which offers training for American medical professionals. He then proceeded to intern at the University of Colorado in general surgery. Dr. Fineberg completed his residency at New York Medical College where he spent most of his training at Westchester Medical Center, a tertiary referral center that specializes in complex care of severely injured trauma patients, as well as Maria Fareri Children’s Hospital which treats children with a variety of complex conditions. Dr. Fineberg completed a year in research in addition to a clinical fellowship in spinal surgery at Chicago’s Rush University Medical Center and Shriner’s Hospital for Children. He worked with world-renowned specialists while at Rush University Medical Center, focusing on improving patient safety and further developing minimally invasive surgical techniques.

Today, Dr. Fineberg consistently interacts with and contributes to a growing body of research regarding the identification and treatment of congenital deformations, spinal defects, and diseases of the vertebral column. He has conducted his own original studies, presented more than 150 times at multiple medical conferences, and contributed to scores of scholarly articles and medical publications. In a 2014 study, Dr. Fineberg investigated the safety of utilizing Bone Morphogenetic Proteins (BMP) in spinal fusions by reviewing all potential complications reported in the literature.

During his career, Dr. Fineberg has conducted numerous anterior and posterior lumbar fusions, cervical fusions and disc replacements, correction of scoliosis, and other traditional and minimally invasive surgical procedures. His philosophy of treatment focuses on maximizing patient outcomes so that they can quickly regain mobility and achieve optimal health. Dr. Fineberg speaks multiple languages, including Hebrew. He associates with multiple area hospitals such as Advocate Lutheran General Hospital (Park Ridge), Northwest Community Hospital (Arlington Heights), and Amita Health Resurrection Medical Center (Chicago). Dr. Fineberg is excited to help with any and all of his new patients’ back, neck, or spine-related issues.

Dr. Fineberg will also be accepting patients Wednesday evenings 2:00 pm – 7:00 pm and on the first Saturday of each month starting Monday, February 3rd, 2020.

To schedule an appointment with Dr. Steven Fineberg, please call (847) 628-8147.

Share article on social media or email:

RALEIGH, N.C. (PRWEB)
January 28, 2020

DiabetesSisters is pleased to welcome Barbara Eichorst, MS, RD, CDE, and Heather Walker, Ph.D., to its Board of Directors, and the appointment of Michele Polz to the position of Board Chair, effective January 24, 2020. As Board Members, Ms. Eichorst and Dr. Walker will join Ms. Polz and existing board members in setting DiabetesSisters-related policies, fundraising, and representing the organization to the community.

Barbara Eichorst, MS, RD, CDE, joined Voluntis in January 2018 as a Diabetes Clinical Liaison. Before Voluntis, Ms. Eichorst worked with Healthy Interactions as Vice President of Clinical Care on a global program that involved over 120 countries. With the Conversation Map program, she has traveled to over 40 countries within the last eleven years. Her vast experience includes work in Chicago as an insulin education specialist and a medical liaison, as well at the American Association of Diabetes Educators as a program director and Chicago-based Rush University Medical Center. She has provided patient education in diabetes, weight management, cardiovascular disease, among many other chronic conditions at Loyola University Medical Center and Northwestern Memorial Hospital. She has contributed to multiple publications with her expertise in change activation, empowerment, and engagement.

Heather Walker is a Social Scientist at the University of Utah Health. She earned her Ph.D. in Disability Studies with a dissertation research project focused on representation in diabetes online communities. Dr. Walker believes focuses on research that involves action, and one section her dissertation was dedicated to facilitating a Peer Collaborator action workgroup, resulting in the social media movement #IHearYou. Aside from her dissertation research, she has published research articles in The Diabetes Educator, The Journal of Diabetes Science and Technology, and Participations: International Journal of Audience Research. Heather has been living with diabetes since 2001, and has been a part of diabetes online communities since 2012.

Michele Polz was elected to the DiabetesSisters board in 2016 and served in the role of Vice-Chair. She is the founder and principal of M1 Consulting, where she collaborates with clients to design impactful data-driven customer acquisition and retention models leading to bottom-line results. She is currently advising within Digital Health Technology and Biotech/ Pharma companies from early discovery through lifecycle management, focusing on integrated care and value-based models. Before consulting, Michele spent the last eight years in Life Sciences, both at Sanofi and Biogen. She is an advocate for putting the patient first.

“We welcome the expertise and experience that Ms. Eichorst, Dr. Walker, and Ms. Polz bring to DiabetesSisters Board of Directors. Through their leadership, we will further the organization’s mission and reach more women with diabetes in need of our programs and services,” said Anna Norton, MS, CEO of DiabetesSisters.

About DiabetesSisters:

A 501(c)3 nonprofit, DiabetesSisters is the only organization nationwide focusing exclusively on women living with diabetes. Our mission is to improve the health and quality of life of women living with and at risk of developing diabetes and to advocate on their behalf. DiabetesSisters has a nearly 50,000-member peer network that united women with diabetes for the purpose of support, education and advocacy. Signature programs include monthly peer support meetings (PODS Meetups); the Minority Initiative Program; Annual Leadership Institute for volunteer leaders; online expert articles, blog posts, forums; and conference. For more information, visit http://www.diabetessisters.org.

Share article on social media or email: